Aortic & peripheral vascular disease

Intravascular Ultrasound-Guided vs Angiography-Guided Drug-Coated Balloon Angioplasty in Patients With Complex Femoropopliteal Artery Disease

JACC Cardiovasc IntervPublished Secondary analysis of the IVUS-DCB randomised trial

Corrected 23 Oct 2026: Measure wording clarified; no values changed.

Authors' conclusion

In endovascular treatment of FPA using DCB, IVUS guidance was significantly associated with improved 12-month clinical outcomes, particularly in patients with complex FPA lesions.

Study context

Population
Patients with femoropopliteal artery disease undergoing DCB angioplasty, by complex (TASC II C/D) or noncomplex (TASC II A/B) lesions158 complex, 79 noncomplex
Participants
237 patients
Comparison
Intravascular ultrasound (IVUS)-guided vs angiography-guided DCB angioplasty
Primary endpoint
Primary patency
Follow-up
12 months
Methodological detailsprespecified subgroup analysis
  • Prespecified subgroup analysis

Primary result

As reported in the abstract

Primary patency, by lesion complexity (subgroups)
IVUS vs AngiographyEstimate (95% CI)P value
Complex FPA: 82.1%vs 60.3%; HR for loss of primary patency
HR for loss of primary patency 0.34(0.16–0.70)
P = 0.002
Noncomplex FPA: 87.5% vs 88.2%
HR 1.84 (0.39–8.60), event not clearly stated
P = 0.44

Secondary outcomes

Freedom from CD-TLR (complex FPA)

HR 0.31 (0.13–0.75) · P = 0.01

Sustained clinical and hemodynamic improvement (complex femoropopliteal artery (FPA))

Significantly higher with IVUS vs angiography guidance

Secondary endpoints (noncomplex FPA)

No significant difference between IVUS and angiography guidance

Original publication

Intravascular Ultrasound-Guided vs Angiography-Guided Drug-Coated Balloon Angioplasty in Patients With Complex Femoropopliteal Artery Disease. JACC Cardiovasc Interv. Published 22 January 2025. doi:10.1016/j.jcin.2024.10.052

Composed by AI from the published abstract and checked against it. How Briefs are made →

Get them every week

New studies on this topic in My Week and in your Monday e-mail.

We e-mail you a sign-in link and a code. No password, no spam.